A Study of KC1036 in Patients with Advanced Solid Tumors

Inclusion Criteria: * Histologically or cytologically confirmed recurrent or metastatic solid tumors; * Patients who have failed standard or conventional treatment, Including chemotherapy, targeted therapy, immunotherapy: Documented disease progression after, or refractory to, or intolerant of prior standard or established therapy known to provide clinical benefit for their condition; or documented disease progression within 24 weeks after prior adjuvant/neoadjuvant therapy; * At least one measurable lesion (by RECIST 1.1); * Eastern Cooperative Oncology Group performance status score of 0 or 1; * Life expectancy \> 12 weeks; * Patients should participate in the study voluntarily and sign informed consent. Exclusion Criteria: * Untreated brain metastases or symptoms of brain metastases cannot be controlled more than 4 weeks; * Other kinds of malignancies; * Hematologic, renal, and hepatic function abnormities; * Risk of bleeding; * Gastrointestinal abnormalitiest; * Cardiovascular and cerebrovascular diseases; * Prior anti-tumor therapies with chemotherapy, radiotherapy, hormonotherapy, biotherapy, immunotherapy, operation within 4 weeks of enrollment; * Presence of unresolved toxicities from prior anti-tumor therapy, defined as having not resolved to NCI CTCAE V5.0 grade 0 or 1 with the exception of alopecia; * Involved in other clinical trials within 4 weeks of enrollment; * Major surgical procedure, open biopsy, or significant traumatic injury 4 weeks days of enrollment; * History of organ allograft; * Need immunosuppressive agents or systemic or absorbable topical hormone therapy for immunosuppression; * Uncontrolled ongoing or active infection; * Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy; * Pregnant or lactating women or those who do not take contraceptives, including men; * Suffering from mental and neurological diseases; * Any other metabolic dysfunction, abnormal physical examination findings, or clinical laboratory findings; * Inability to comply with protocol required procedures.